Intestinal Research

Review

IBD

Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease: You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko; Intest Res 2023;21(4):420-432. Published online September 1, 2023; DOI: https://doi.org/10.5217/ir.2023.00039

Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with this disease have an increased risk of malignancy development, such as colorectal cancer and cholangiocarcinoma. The pathogenesis of PSC-IBD involves genetic and environmental factors such as gut dysbiosis and bile acids alteration. However, despite the advancement of disease characteristics, no effective medical therapy has proven to have a significant impact on the prognosis of PSC. The treatment options for patients with PSC-IBD do not differ from those for patients with PSC alone. Potential candidate drugs have been developed based on the pathogenesis of PSC-IBD, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis. In this review, we summarize the current medical treatments for PSC-IBD and the status of new emerging therapeutic agents.

Citations

Citations to this article as recorded by

Fecal calprotectin in patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis
Giorgia Burrelli Scotti, Fabrizio Zullo, Marco Mattana, Francesco Covotta, Emanuela Ribichini, Domenico Alvaro, Vincenzo Cardinale
Clinics and Research in Hepatology and Gastroenterology.2026; 50(2): 102764. CrossRef
Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease
Haruka Okada, Shinya Sugimoto, Atsuto Kayashima, Yohei Mikami, Takanori Kanai, Nobuhiro Nakamoto, Yusuke Yoshimatsu, Hiroki Kiyohara, Yukie Nakadai, Ryosuke Kasuga, Nobuhito Taniki, Keisuke Ojiro, Shingo Usui, Shogo Sunaga, Ichiro Mizushima, Yuta Kaieda,
Journal of Gastroenterology.2026;[Epub] CrossRef
Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology
Inyoung Cheon, Minwook Kim, Kang Ho Kim, Sungjin Ko
The American Journal of Pathology.2025; 195(3): 409. CrossRef
Documento de posicionamiento de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN) y del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el manejo de la enfermedad inflamatoria intestinal en atención primari
Daniel Ginard, Noelia Fontanillas, Iria Bastón-Rey, M. Elena Pejenaute, Marta Piqueras, Silvia Alcalde, Pilar Nos, Mercedes Ricote, Lucía Expósito, Míriam Mañosa, Manuel Barreiro-de Acosta, Francisco Rodríguez-Moranta, Yamile Zabana, José Polo, Ana Gutiér
Gastroenterología y Hepatología.2025; 48(3): 502255. CrossRef
Documento de posicionamiento de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN) y del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el manejo de la enfermedad inflamatoria intestinal en atención primari
Daniel Ginard, Noelia Fontanillas, Iria Bastón-Rey, M. Elena Pejenaute, Marta Piqueras, Silvia Alcalde, Pilar Nos, Mercedes Ricote, Lucía Expósito, Míriam Mañosa, Manuel Barreiro-de Acosta, Francisco Rodríguez-Moranta, Yamile Zabana, José Polo, Ana Gutiér
Medicina de Familia. SEMERGEN.2025; 51(3): 102334. CrossRef
Position statement of the Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the management of inflammatory bowel disease in Primary Care
Daniel Ginard, Noelia Fontanillas, Iria Bastón-Rey, M. Elena Pejenaute, Marta Piqueras, Silvia Alcalde, Pilar Nos, Mercedes Ricote, Lucía Expósito, Míriam Mañosa, Manuel Barreiro-de Acosta, Francisco Rodríguez-Moranta, Yamile Zabana, José Polo, Ana Gutiér
Gastroenterología y Hepatología (English Edition).2025; 48(3): 502255. CrossRef
Incidence, Risk Factors, and Outcomes of Chronic Antibiotic-Refractory Pouchitis in Korean Patients with Ulcerative Colitis
Ji Eun Baek, Jung-Bin Park, June Hwa Bae, Min Hyun Kim, Seung Wook Hong, Sung Wook Hwang, Jong Lyul Lee, Yong Sik Yoon, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Chang Sik Yu, Suk-Kyun Yang, Sang Hyoung Park
Gut and Liver.2025; 19(3): 388. CrossRef
Prevalence and risk factors of gallstone disease in Korean patients with ulcerative colitis
Kwangwoo Nam, Jae Yong Lee, Sang Hyoung Park, Ha Won Hwang, Ho-Su Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Jin Hwa Park, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Intestinal Research.2025; 23(4): 455. CrossRef
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Aalam Sohal, Kris V. Kowdley
Expert Opinion on Investigational Drugs.2024; 33(4): 335. CrossRef
Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications
Valeria Maccauro, Francesca Fianchi, Antonio Gasbarrini, Francesca Romana Ponziani
Digestive Diseases.2024; 42(4): 369. CrossRef
Global research trends on the relationship between IBD and CRC: a bibliometric analysis from 2000 to 2023
Hao Zhang, Huiru Xin, Mengqi Zhao, Chenyang Bi, Yafei Xiao, Yifan Li, Changjiang Qin
Journal of Health, Population and Nutrition.2024;[Epub] CrossRef
Halitosis: an underestimated but important extraintestinal manifestation in inflammatory bowel disease
Xiao Xian Qian
Intestinal Research.2024; 22(3): 387. CrossRef
Phenotypes of primary sclerosing cholangitis in children
M.B. Dyba, V.S. Berezenko
GASTROENTEROLOGY.2024; 58(4): 270. CrossRef

17,864 View
667 Download
12 Web of Science
13 Crossref

First
Prev
Page of 1
Next
Last

Search